Sangsangin raises target for Dongkook Pharmaceutical stock to KRW 33,000

Published on 10/14/2026 at 02:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DK Centellian vote is set for November 27, 2026. Dongkook Pharmaceutical stock links to 28.70 percent healthcare growth in first half of 2026.

Global beauty strategy advances

Sangsangin raised its Dongkook target to KRW 33,000 on October 13, 2026.
Healthcare revenue reached KRW 202.9 billion in the first half of 2026, up 28.70 percent.
The extraordinary shareholder meeting is scheduled for November 27, 2026, after 58 years under the Dongkook name.

Dongkook, KR7086450004, Illustration mit AI erstellt.

Dongkook Pharmaceutical plans a name change to DK Centellian as Sangsangin Investment & Securities raised its target from KRW 30,000 to KRW 33,000 on October 13, 2026. The analyst kept a Buy rating, making overseas cosmetics growth the key argument behind the revised valuation.

Three dated steps toward expansion

On October 2, 2026, IBK Investment & Securities initiated coverage with a KRW 30,000 target and projected second-half revenue of KRW 547.5 billion, according to Edaily. On October 9, 2026, Dongkook's first-half revenue was reported at KRW 509.9 billion, with operating profit of KRW 53.4 billion, according to Seoul Economic Daily. On October 13, 2026, the board resolved to pursue the DK Centellian name and a broader global health and beauty strategy, Edaily reported.

What does the name change add?

The proposed name links Dongkook's 58-year history to a wider business scope covering prevention, treatment, health and beauty. The extraordinary general meeting is scheduled for November 27, 2026, when shareholders will consider changes to the articles of incorporation, according to Edaily.

Cosmetics carry the earnings case

Healthcare sales, including cosmetics, reached KRW 202.9 billion in the first half of 2026, up 28.70 percent from a year earlier, according to Seoul Economic Daily. The segment represented a larger share of the group than in 2023, while IBK projected second-half healthcare revenue of KRW 213.2 billion, up 34.30 percent year over year. That combination gives the name change a measurable operating test: overseas distribution must convert the cosmetics expansion into revenue and profit.

Next corporate milestone

Investors now have a dated governance checkpoint rather than only an aspirational branding message. The November 27 meeting will determine whether the proposed DK Centellian identity advances, while the KRW 33,000 target from Sangsangin provides the latest linked analyst benchmark for the expansion story.

Market context: Market report KOSPI.